Tarsus Pharmaceuticals

#Ophthalmology #Parasitic disease #Vector-borne disease

Late clinical-stage biopharma developing therapeutic solutions for chronic diseases in eye care and beyond; lead product XDEMVY (lotilaner ophthalmic solution 0.25%) is the first and only FDA-approved treatment for Demodex blepharitis. In August 2026 it agreed to acquire Alkeus Pharmaceuticals and its Phase 3 Stargardt disease drug for $450 million.

Company Info

Sector:Ophthalmology / Biopharmaceuticals

Headquarters:Irvine, California, USA

Founded:2016

Website:tarsusrx.com/

Upcoming Milestones & Key Dates

2026-08

M&A

Alkeus Pharmaceuticals acquisition announced ($450M)

2026-08

Pipeline

Acquired Stargardt disease program integration

Clinical Development Pipeline

XDEMVY (lotilaner 0.25%)

Target: Parasitic (Demodex mites)

Demodex blepharitis

Preclinical

Phase 1

Phase 2

Phase 3

Approved

TP-04

Target: Investigational gel

Ocular rosacea

Preclinical

Phase 1

Phase 2

Phase 3

Approved

TP-05

Target: Oral systemic antiparasitic

Vector-targeting prophylaxis

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition ↗

Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition

Leadership Team

Bobak 'Bobby' Azamian

Chairman, President and CEO (co-founder)

Michael Ackermann

Co-founder

Careers & Job Openings

See all open roles

Apply Now →